<DOC>
	<DOCNO>NCT01575756</DOCNO>
	<brief_summary>The purpose study investigate pharmacokinetic property , surrogate efficacy safety Octafibrin compare Haemocomplettan® P/RiaSTAPTM patient congenital fibrinogen deficiency</brief_summary>
	<brief_title>Pharmacokinetic , Efficacy , Safety Study Octafibrin Compared Haemocomplettan/Riastap</brief_title>
	<detailed_description />
	<mesh_term>Afibrinogenemia</mesh_term>
	<criteria>Age ≥ 12 year . Documented congenital fibrinogen deficiency ( afibrinogenemia ) . Life expectancy &gt; 6 month . Bleeding disorder congenital fibrinogen deficiency . Presence history hypersensitivity study medication . Presence history deep vein thrombosis pulmonary embolism within 1 year prior enrollment . Presence history arterial thrombosis 1 year prior enrollment . Hypersensitivity human plasma product . Acute bleeding . Pregnant currently breastfeed woman . Suspicion antifibrinogen inhibitor indicate previous vivo recovery ( available ) . Blood plasma donation 3 month prior enrollment . Human immunodeficiency virus ( HIV ) positive viral load &gt; 200 particles/µl &gt; 400000 copies/mL . Endstage liver disease . History oesophageal varicose bleed .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>